Dr. Reddy’s Laboratories Ltd – Consensus Says Potential 7.4% Increase


Dr Reddy Laboratories Ltée with ticker code (RDY) now have 2 analysts covering the stock with consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and the low target price is between 81.55 and 80, with the average target price being 80.78. Now, with the previous closing price of 75.19, this now indicates that there is a potential upside of 7.4%. The 50-day moving average now stands at 72.46 while the 200-day moving average is 67.41. The company’s market capitalization is $ 12,482 million. Company website: http://www.drreddys.com

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as a globally integrated pharmaceutical company. It operates through the Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as generic finished strengths having therapeutic equivalence with branded formulations. This segment is also active in the organic products sector. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are the main ingredients of finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with specific customer requirements. The Proprietary Products segment focuses on the research, development and commercialization of differentiated formulations for the therapeutic areas of dermatology and neurology. The Others segment is dedicated to the development of therapies in the fields of oncology and inflammation. As of March 31, 2021, the company had three late stage projects in various stages of development. Its therapeutic categories are mainly gastrointestinal, cardiovascular, antidiabetic, dermatological, oncological, respiratory, stomatological, urological and nephrological. The company has a collaboration, license and option agreement with Curis to discover, develop and commercialize small molecule antagonists for precision immuno-oncology and oncology targets. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

You can now share this on Stocktwits, just click on the logo below and add the ticker in the text to be seen.


Leave A Reply